CY1110214T1 - Μεθοδοι και ενδιαμεσα - Google Patents

Μεθοδοι και ενδιαμεσα

Info

Publication number
CY1110214T1
CY1110214T1 CY20101100613T CY101100613T CY1110214T1 CY 1110214 T1 CY1110214 T1 CY 1110214T1 CY 20101100613 T CY20101100613 T CY 20101100613T CY 101100613 T CY101100613 T CY 101100613T CY 1110214 T1 CY1110214 T1 CY 1110214T1
Authority
CY
Cyprus
Prior art keywords
methods
intermediates
protease inhibitors
useful
compounds
Prior art date
Application number
CY20101100613T
Other languages
English (en)
Inventor
Gerald J Tanoury
Minzhang Chen
John E Cochran
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of CY1110214T1 publication Critical patent/CY1110214T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link

Abstract

Η εφεύρεση αφορά ενώσεις και μεθόδους χρήσιμες για τη παρασκευή αναστολέων πρωτεάσης, ιδιαιτέρως αναστολέων προτεάσης σερίνης. Οι αναστολείς πρωτεάσης είναι χρήσιμοι για θεραπεία μολύνσεων HCV.
CY20101100613T 2005-08-19 2010-07-05 Μεθοδοι και ενδιαμεσα CY1110214T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70996405P 2005-08-19 2005-08-19
US81004206P 2006-06-01 2006-06-01
EP06813568A EP1934179B1 (en) 2005-08-19 2006-08-18 Processes and intermediates

Publications (1)

Publication Number Publication Date
CY1110214T1 true CY1110214T1 (el) 2015-01-14

Family

ID=37708299

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20101100613T CY1110214T1 (el) 2005-08-19 2010-07-05 Μεθοδοι και ενδιαμεσα
CY20141100149T CY1114916T1 (el) 2005-08-19 2014-02-25 Μεθοδοι

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20141100149T CY1114916T1 (el) 2005-08-19 2014-02-25 Μεθοδοι

Country Status (25)

Country Link
US (3) US7776887B2 (el)
EP (4) EP2194043B1 (el)
JP (1) JP5203203B2 (el)
KR (4) KR20130038947A (el)
CN (2) CN101291909B (el)
AR (1) AR058025A1 (el)
AT (1) ATE463480T1 (el)
AU (1) AU2006279357B2 (el)
BR (1) BRPI0615029A2 (el)
CA (1) CA2619659A1 (el)
CY (2) CY1110214T1 (el)
DE (1) DE602006013492D1 (el)
DK (2) DK2194043T3 (el)
ES (2) ES2449268T3 (el)
HK (2) HK1122801A1 (el)
IL (2) IL189585A (el)
NZ (3) NZ604087A (el)
PL (3) PL385229A1 (el)
PT (2) PT1934179E (el)
RU (2) RU2446171C2 (el)
SG (1) SG2014013338A (el)
SI (2) SI1934179T1 (el)
TW (2) TW201245149A (el)
WO (1) WO2007022459A2 (el)
ZA (1) ZA200801791B (el)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA979327B (en) * 1996-10-18 1998-05-11 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease.
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
UY28500A1 (es) * 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
CA2617679A1 (en) * 2005-08-02 2007-02-08 Steve Lyons Inhibitors of serine proteases
ATE463480T1 (de) 2005-08-19 2010-04-15 Vertex Pharma Verfahren und zwischenprodukte
US8399615B2 (en) * 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
AU2007217355B2 (en) 2006-02-27 2012-06-21 Vertex Pharmaceuticals Incorporated Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same
CA2646123A1 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Processes and intermediates for preparing steric compounds
AU2007227544B2 (en) 2006-03-16 2012-11-01 Vertex Pharmaceuticals Incorporated Deuterated hepatitis C protease inhibitors
WO2008076316A2 (en) * 2006-12-15 2008-06-26 Schering Corporation Bisulfite purification of an alpha-keto amide
TW200846343A (en) * 2007-02-27 2008-12-01 Vertex Pharma Co-crystals and pharmaceutical compositions comprising the same
JP2010519329A (ja) * 2007-02-27 2010-06-03 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ阻害剤
US8492546B2 (en) * 2007-08-30 2013-07-23 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
US8431733B2 (en) * 2008-03-12 2013-04-30 Virobay, Inc. Process for the preparation of (3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamide derivatives
WO2009152474A2 (en) * 2008-06-13 2009-12-17 Virobay, Inc. Process for the preparation of (3s)-3-amino-n-cyclopropyl-2-hydroxyalkanamide derivatives
EP2307419B1 (en) 2008-06-24 2013-11-06 Codexis, Inc. Biocatalytic processes for the preparation of substantially stereomerically pure fused bicyclic proline compounds
US8686145B2 (en) * 2010-02-25 2014-04-01 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patientenzorg C/O Technology Transfer Officer VU & Vumc Process for the preparation of α-acyloxy β-formamido amides
CN103108865A (zh) 2010-06-03 2013-05-15 弗特克斯药品有限公司 方法和中间体
CN102167680B (zh) * 2011-03-23 2014-07-02 合亚医药科技（上海）有限公司 八氢环戊基并[c]吡咯羧酸衍生物的制备方法
WO2012158513A1 (en) 2011-05-13 2012-11-22 Vertex Pharmaceuticals Incorporated Processes and intermediates
CN103748059A (zh) * 2011-05-13 2014-04-23 弗特克斯药品有限公司 制备蛋白酶抑制剂的方法
JP2013010738A (ja) * 2011-05-31 2013-01-17 Sumitomo Chemical Co Ltd エステル化合物の製造方法
JP5677645B2 (ja) 2011-10-21 2015-02-25 アッヴィ・インコーポレイテッド 少なくとも２種の直接作用型抗ウイルス剤、およびリバビリンを含むがインターフェロンを含まない、ｈｃｖを治療するための方法
CN104436197A (zh) 2011-10-21 2015-03-25 艾伯维公司 至少两种直接作用抗病毒剂的组合产品
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
WO2013072328A1 (en) 2011-11-14 2013-05-23 Sanofi Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
CN103183632A (zh) * 2011-12-29 2013-07-03 山东方明药业集团股份有限公司 一种3-氮杂双环辛烷盐酸盐的提纯方法
ITMI20120192A1 (it) 2012-02-13 2013-08-14 Dipharma Francis Srl Procedimento per la preparazione di un inibitore delle proteasi virali e suoi intermedi
ITMI20120359A1 (it) 2012-03-07 2013-09-08 Dipharma Francis Srl Procedimento per la preparazione di intermedi utili nella preparazione di un inibitore delle proteasi virali
ITMI20121668A1 (it) * 2012-10-05 2014-04-06 Dipharma Francis Srl Sintesi di un intermedio di un composto antivirale
WO2013136265A1 (en) 2012-03-13 2013-09-19 Dipharma Francis S.R.L. Synthesis of an intermediate of an antiviral compound
ITMI20120391A1 (it) * 2012-03-13 2013-09-14 Dipharma Francis Srl Procedimento per la sintesi di un intermedio ciclopropilammidico utile nella preparazione di un inibitore delle proteasi virali
IN2014DN08260A (el) 2012-03-16 2015-05-15 Sandoz Ag
ITMI20120608A1 (it) 2012-04-13 2013-10-14 Dipharma Francis Srl Procedimento per la preparazione di un inibitore delle proteasi virali in forma amorfa
ITMI20120800A1 (it) * 2012-05-10 2013-11-11 Dipharma Francis Srl Procedimento per la preparazione di un intermedio utile nella preparazione di un inibitore delle proteasi virali
WO2013178682A2 (en) 2012-05-30 2013-12-05 Chemo Ibérica, S.A. Multicomponent process for the preparation of bicyclic compounds
CN103450066B (zh) * 2012-05-30 2017-03-15 博瑞生物医药（苏州）股份有限公司 特拉匹韦中间体的制备方法
ITMI20120990A1 (it) * 2012-06-07 2013-12-08 Dipharma Francis Srl Sintesi di un inibitore delle proteasi virali
WO2013189978A1 (en) 2012-06-20 2013-12-27 Sandoz Ag PROCESS FOR PREPARING ß-AMINO ACID DERIVATIVES AND USE OF SAID PROCESS FOR PREPARING TELAPREVIR
CN104470914A (zh) * 2012-06-20 2015-03-25 桑多斯股份公司 替拉瑞韦和波普瑞韦或者其药学上可接受的盐或溶剂合物和中间产物包括经Mukaiyama羟醛加成制备的β-氨基酸的合成
WO2014019179A1 (zh) * 2012-08-01 2014-02-06 上海迪赛诺药业有限公司 特拉匹韦及其中间体的制备方法
WO2014033667A1 (en) 2012-08-30 2014-03-06 Ranbaxy Laboratories Limited Process for the preparation of telaprevir
CN102875648B (zh) * 2012-09-26 2014-02-19 深圳翰宇药业股份有限公司 一种制备特拉匹韦的方法
WO2014053533A1 (en) 2012-10-05 2014-04-10 Sanofi Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
ITMI20122036A1 (it) 2012-11-29 2014-05-30 Dipharma Francis Srl Sintesi di un intermedio di un composto antivirale
WO2014096374A1 (en) 2012-12-21 2014-06-26 Sandoz Ag Process for the synthesis of pyrrolidines and pyrroles
CN104870439A (zh) * 2012-12-21 2015-08-26 桑多斯股份公司 替拉瑞韦的新形式
CN103936651B (zh) * 2013-01-18 2016-06-22 上海医药工业研究院 抗丙肝药物Boceprevir的中间体Ⅲ及其制备方法和应用
ITMI20130706A1 (it) * 2013-04-30 2014-10-31 Dipharma Francis Srl Procedimento per la preparazione di un inibitore delle proteasi virali e suoi intermedi
CN103288671B (zh) * 2013-06-20 2014-10-29 上海步越化工科技有限公司 一种(3s)-3-氨基-n-环丙基-2-羟基己酰胺盐酸盐的合成方法
WO2014203208A1 (en) 2013-06-21 2014-12-24 Ranbaxy Laboratories Limited Process for the preparation of telaprevir and intermediates thereof
WO2014203224A1 (en) 2013-06-21 2014-12-24 Ranbaxy Laboratories Limited Process for the preparation of telaprevir and its intermediates
CN104292146B (zh) * 2013-06-24 2017-04-26 上海医药工业研究院 特拉匹韦中间体及其制备方法
CN103342656B (zh) * 2013-07-04 2015-04-08 苏州永健生物医药有限公司 特拉匹韦中间体的合成方法
CN103435532B (zh) * 2013-09-02 2015-07-08 苏州永健生物医药有限公司 波普瑞韦中间体的合成方法
WO2015036522A1 (en) * 2013-09-13 2015-03-19 Sandoz Ag Process for the preparation and isolation of (s)-3-amino-n-cyclopropyl-2,2-dialkoxyhexanamide and (s)-tert-butyl(1-(cyclopropylamino)-2,2-dialkoxy-1-oxohexan-3-yl)carbamate and use thereof for the preparation of telaprevir
US9982014B2 (en) 2013-10-23 2018-05-29 Kaneka Corporation Tetrapeptide compound and method for producing same
CN103664739B (zh) * 2013-12-10 2016-04-27 湖南科源生物制品有限公司 一种特拉匹韦中间体的制备方法
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
CN105646329A (zh) * 2014-11-28 2016-06-08 重庆圣华曦药业股份有限公司 一种制备特拉匹韦中间体的方法
CN105111129A (zh) * 2015-08-24 2015-12-02 上海合全药业股份有限公司 (1S,3aR,6aS)-八氢环戊烯并[C]吡咯-1-羧酸叔丁酯草酸盐的制备方法
CN105601556B (zh) * 2015-12-02 2018-11-13 镇江市高等专科学校 特拉匹韦双环吡咯烷中间体的制备方法
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALCYNE-CONTAINING NUCLEOTIDES AND NUCLEOSIDES THERAPEUTIC COMPOSITIONS AND USES THEREOF
KR20210098504A (ko) 2018-12-04 2021-08-10 브리스톨-마이어스 스큅 컴퍼니 다중 동위원소체 반응 모니터링에 의한 샘플내 보정 곡선을 사용한 분석 방법
US11952365B2 (en) 2020-06-10 2024-04-09 Aligos Therapeutics, Inc. Anti-viral compounds
CA3224494A1 (en) 2021-07-09 2023-01-12 Koen Vandyck Anti-viral compounds

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3211676A1 (de) 1982-03-30 1983-10-06 Hoechst Ag Neue derivate von cycloalka (c) pyrrol-carbonsaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue cycloalka (c) pyrrol-carbonsaeuren als zwischenstufen und verfahren zu deren herstellung
US5468858A (en) * 1993-10-28 1995-11-21 The Board Of Regents Of Oklahoma State University Physical Sciences N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
JPH0967344A (ja) * 1995-09-05 1997-03-11 Koei Chem Co Ltd 光学活性ｎ−ベンジルオキシカルボニルピペコリン酸の製造方法
EP0907659A1 (en) 1996-05-10 1999-04-14 Schering Corporation Synthetic inhibitors of hepatitis c virus ns3 protease
JP3863230B2 (ja) 1996-08-16 2006-12-27 株式会社カネカ β−アミノ−α−ヒドロキシ酸誘導体の製造方法
ZA979327B (en) 1996-10-18 1998-05-11 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease.
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
GB9707659D0 (en) 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
NZ503262A (en) 1997-08-11 2002-10-25 Boehringer Ingelheim Ca Ltd Hepatitis C NS3 protease inhibitor peptides and peptide analogues
DE69827956T2 (de) 1997-08-11 2005-04-14 Boehringer Ingelheim (Canada) Ltd., Laval Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
IT1299134B1 (it) 1998-02-02 2000-02-29 Angeletti P Ist Richerche Bio Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
ES2281170T3 (es) 1998-03-31 2007-09-16 Vertex Pharmaceuticals Incorporated Inhibidores de serina proteasas, particularmente proteasa ns3 del virus de la hepatitis c.
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
DE19836514A1 (de) 1998-08-12 2000-02-17 Univ Stuttgart Modifikation von Engineeringpolymeren mit N-basischen Gruppe und mit Ionenaustauschergruppen in der Seitenkette
GB9825946D0 (en) 1998-11-26 1999-01-20 Angeletti P Ist Richerche Bio Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
AU2943400A (en) 1999-03-12 2000-10-04 Ajinomoto Co., Inc. Process for the preparation of alpha-aminoketone derivatives
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US7122627B2 (en) 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
EP1206449A1 (en) 1999-07-26 2002-05-22 Bristol-Myers Squibb Company Lactam inhibitors of hepatitis c virus ns3 protease
EP1261611A2 (en) 2000-02-29 2002-12-04 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
US6849599B2 (en) * 2000-03-08 2005-02-01 Rhode Island Hospital Combination drug therapy
ES2240446T3 (es) 2000-04-03 2005-10-16 Vertex Pharma Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
EP1268525B1 (en) 2000-04-05 2008-12-31 Schering Corporation Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
AR030558A1 (es) 2000-04-19 2003-08-27 Schering Corp COMPUESTOS MACROCICLICOS, QUE INCLUYEN ENANTIOMEROS, ESTEROISOMEROS, ROTAMEROS Y TAUTOMEROS, SALES Y SOLVATOS FARMACEUTICAMENTE ACEPTABLES, COMPOSICIoN FARMACEUTICA, UN METODO PARA SU PREPARACION Y EL USO DE DICHOS COMPUESTOS PARA LA ELABORACION DE UN MEDICAMENTO, INHIBIDORES DE LA SERINA PROTEASA,
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
HU229997B1 (en) 2000-07-21 2015-04-28 Dendreon Corp San Diego Peptides as ns3-serine protease inhibitors of hepatitis c virus
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
HUP0303358A3 (en) 2000-07-21 2005-10-28 Schering Corp Novel peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
WO2002060926A2 (en) 2000-11-20 2002-08-08 Bristol-Myers Squibb Company Hepatitis c tripeptide inhibitors
AU2002230763A1 (en) 2000-12-13 2008-01-03 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
US6653295B2 (en) 2000-12-13 2003-11-25 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus NS3 protease
US6727366B2 (en) 2000-12-13 2004-04-27 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors
GB0107924D0 (en) 2001-03-29 2001-05-23 Angeletti P Ist Richerche Bio Inhibitor of hepatitis C virus NS3 protease
MXPA04000293A (es) 2001-07-11 2004-05-04 Vertex Pharma Inhibidores de serina proteasa biciclica de puente.
EP1441720B8 (en) * 2001-10-24 2012-03-28 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
EP1590442A4 (en) 2003-02-07 2007-07-18 Enanta Pharm Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
US20040180815A1 (en) 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
TW200510391A (en) 2003-04-11 2005-03-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
BRPI0414814A (pt) * 2003-09-26 2006-11-14 Schering Corp inibidores macrocìclicos de protease de serina ns3 de vìrus de hepatite c
ATE438622T1 (de) 2004-02-27 2009-08-15 Schering Corp 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
ATE463480T1 (de) 2005-08-19 2010-04-15 Vertex Pharma Verfahren und zwischenprodukte
US8258116B2 (en) 2007-05-04 2012-09-04 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection

Also Published As

Publication number Publication date
US8637457B2 (en) 2014-01-28
US20100174077A1 (en) 2010-07-08
TW201245149A (en) 2012-11-16
WO2007022459A2 (en) 2007-02-22
DE602006013492D1 (de) 2010-05-20
NZ566049A (en) 2011-07-29
RU2446171C2 (ru) 2012-03-27
WO2007022459A3 (en) 2008-02-28
TWI391376B (zh) 2013-04-01
CY1114916T1 (el) 2016-12-14
PL2194043T3 (pl) 2014-07-31
JP2009504780A (ja) 2009-02-05
EP2194043A2 (en) 2010-06-09
ATE463480T1 (de) 2010-04-15
PL385229A1 (pl) 2008-09-29
PT2194043E (pt) 2014-03-04
US20140107318A1 (en) 2014-04-17
IL228770A0 (en) 2013-12-31
RU2011148615A (ru) 2013-06-10
SI2194043T1 (sl) 2014-04-30
PL1934179T3 (pl) 2010-09-30
HK1145022A1 (en) 2011-03-25
ES2344156T3 (es) 2010-08-19
HK1122801A1 (en) 2009-05-29
RU2008110479A (ru) 2009-09-27
AU2006279357B2 (en) 2012-05-31
IL189585A0 (en) 2008-08-07
CN101291909B (zh) 2012-09-05
US7776887B2 (en) 2010-08-17
IL189585A (en) 2013-10-31
EP1934179A2 (en) 2008-06-25
CN101291909A (zh) 2008-10-22
EP2194043A3 (en) 2010-11-24
NZ604087A (en) 2014-07-25
ES2449268T3 (es) 2014-03-19
KR20140069370A (ko) 2014-06-09
DK1934179T3 (da) 2010-08-09
SG2014013338A (en) 2014-06-27
KR101474405B1 (ko) 2014-12-23
EP2357170A1 (en) 2011-08-17
PT1934179E (pt) 2010-07-12
US20070087973A1 (en) 2007-04-19
JP5203203B2 (ja) 2013-06-05
CA2619659A1 (en) 2007-02-22
NZ593214A (en) 2013-02-22
KR20080047396A (ko) 2008-05-28
ZA200801791B (en) 2008-12-31
PL1934179T4 (pl) 2014-03-31
AR058025A1 (es) 2008-01-23
KR20130038947A (ko) 2013-04-18
BRPI0615029A2 (pt) 2009-06-16
KR20130110236A (ko) 2013-10-08
CN102382170A (zh) 2012-03-21
EP1934179B1 (en) 2010-04-07
EP2194043B1 (en) 2013-12-25
SI1934179T1 (sl) 2010-08-31
AU2006279357A1 (en) 2007-02-22
EP2364970A1 (en) 2011-09-14
DK2194043T3 (da) 2014-01-20
TW200800889A (en) 2008-01-01

Similar Documents

Publication Publication Date Title
CY1110214T1 (el) Μεθοδοι και ενδιαμεσα
CY1119669T1 (el) Παραγωγα 1-φαινυλ-2-πυριδινυλ-αλκυλ-αλκοολων ως αναστολεις φωσφοδιεστερασης
EA200800371A1 (ru) Ингибиторы ns3 протеазы вгс
CY1111212T1 (el) Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ
CY1113314T1 (el) (3-αρυλ-πιπεραζιν-1-υλ) παραγωγα της 6,7-διαλκοξυκιναζολινης, 6,7-διαλκοξυφθαλαζινης και 6,7-διαλκοξυϊσοκινολινης
CY1112630T1 (el) Αναστολεις πυριδυλιου της σηματοδοτησης hedgehog
CY1113752T1 (el) Μακροκυκλικες ενωσεις κινοξαλινης ως αναστολεις πρωτεασεις ns3 του hcv
BRPI0807904A2 (pt) Inibidores das serina proteases para o tratamento de infecções de hcv
CY1106640T1 (el) Αναστολεις κρουζιπαϊνης και αλλων πρωτεασων κυστεϊνης
CY1113560T1 (el) Αζαϊνδολια χρησιμα ως αναστολεις των jak και αλλων πρωτεϊνικων κινασων
MA29135B1 (fr) Potentialisateurs de recepteurs du glutamate
CY1114284T1 (el) Σουλφονυλοπυρρολες ως hdac αναστολεις
CY1117328T1 (el) Διαδικασια για την παρασκευη πολυσιαλικου οξεος υψηλης καθαρiοτητας
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
NO20081086L (no) Makrosykliske peptider som HCV NS3-proteaseinhibitorer
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
ATE497505T1 (de) Makrocyclische inhibitoren der ns3-serinprotease des hepatitis-c-virus
CY1112780T1 (el) Νεα σουλφονυλοπυρρολια ως αναστολεις της ηdac
DK1654360T3 (da) Amplificering fremgangsmåde
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
CY1114075T1 (el) Ενωσεις αλφα κετοαμιδιου ως αναστολεις πρωτεασης κυστεϊνης
DE602005010421D1 (de) Neue Cysteine Protease Hemmers und ihre therapeutische Anwendungen
CL2007001004A1 (es) Compuestos derivados peptidicos, inhibidores de proteasa, utiles para el tratamiento de una infeccion por el virus de la hepatitis c.
EA201000566A1 (ru) Гетероциклические сетр ингибиторы